Ketamine is classified as being a Schedule III controlled substance under the Managed Compound Act and, as noted previously mentioned, approved by the FDA for anesthetic indications [seventy three]. Common adverse effects affiliated with anesthetic ketamine use consist of emergence reactions, hemodynamic instability, and respiratory depression. The… Read More